Press Releases

Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology and Merck, a leading pharmaceutical, chemical and life science company with total revenues of EUR 11.2 billion in 2012, announce today a global prior use license...

Banook Central Imaging (Banook CI), a global imaging core lab for drug and device clinical trials, announces today that it has been selected by Servier to assess the potential anti-tumor activity of a novel monoclonal antibody based on the...

It is a great pleasure of Eureka Science to announce the latest editions of our very successful series of conferences; the “6th International Conference on Drug Discovery and Therapy” and the “3rd Biotechnology World Congress” in Dubai UAE. This...

SPONSORED BY CHEMICAL COMPUTING GROUPSMi are proud to present the 13th annual Advances and Progress in Drug Design conference, convening in Central London on Monday 17 and Tuesday 18 February 2014. This exciting event will focus on new approaches...

Agilent Technologies Inc. and Seoul National University Hospital one of Korea’s top medical centers today announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs including narcotics immune-suppressants and biomarkers. ...

Nosopharm specializes in the research and development of new anti-infective drugs, today announces that it has secured funding of EUR 870,000 (USD 1.18 million). The company is receiving this funding as part of the OOPERA...

Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab an interleukin-17A inhibitor, was significantly superior to Enbrel in moderate-to-severe plaque psoriasis. Enbrel is a current standard-of-care anti-TNF medication approved to treat moderate-to-severe plaque...